References
Filters: Author is Stefan Zeuzem [Clear All Filters]
Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)–infected patients: integrated analysis of phase 2-3 trials [abstract 700]. In: Liver Meeting 2015. Liver Meeting 2015. San Francisco, CA; 2015.
. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910-918.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.